Longitudinal change in CSF biomarkers in a presymptomatic carrier of an APP mutation.
作者信息
Ringman J M, Taylor K, Teng E, Coppola G, Gylys K
机构信息
Easton Center for Alzheimer's Disease Research, UCLA Department of Neurology, Los Angeles, CA 90095-7226, USA
出版信息
Neurology. 2011 Jun 14;76(24):2124-5. doi: 10.1212/WNL.0b013e31821f4488. Epub 2011 May 11.
Abstract
摘要
相似文献
1
Longitudinal change in CSF biomarkers in a presymptomatic carrier of an APP mutation.
Neurology. 2011 Jun 14;76(24):2124-5. doi: 10.1212/WNL.0b013e31821f4488. Epub 2011 May 11.
2
Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
Neurology. 2015 Aug 18;85(7):626-33. doi: 10.1212/WNL.0000000000001859. Epub 2015 Jul 15.
3
Clinical, biological, and imaging features of monogenic Alzheimer's Disease.
Biomed Res Int. 2013;2013:689591. doi: 10.1155/2013/689591. Epub 2013 Nov 27.
4
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.
BMC Neurol. 2009 Dec 22;9:63. doi: 10.1186/1471-2377-9-63.
5
Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.
Neurology. 2012 Jul 17;79(3):229-36. doi: 10.1212/WNL.0b013e31825fdf18. Epub 2012 Jun 13.
6
Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
J Neurosci. 2019 Sep 11;39(37):7428-7437. doi: 10.1523/JNEUROSCI.1056-19.2019. Epub 2019 Jul 26.
7
Microvesicles from cerebrospinal fluid of patients with Alzheimer's disease display reduced concentrations of tau and APP protein.
Sci Rep. 2019 May 8;9(1):7089. doi: 10.1038/s41598-019-43607-7.
8
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.
Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14.
9
Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations.
Arch Neurol. 2012 Jan;69(1):96-104. doi: 10.1001/archneurol.2011.642.
10
Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725.
引用本文的文献
1
Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD.
Front Neurol. 2015 Jun 29;6:142. doi: 10.3389/fneur.2015.00142. eCollection 2015.
2
Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.
JAMA Neurol. 2015 Mar;72(3):316-24. doi: 10.1001/jamaneurol.2014.3314.
3
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.
Sci Transl Med. 2014 Mar 5;6(226):226ra30. doi: 10.1126/scitranslmed.3007901.
4
CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders.
Transl Psychiatry. 2013 Aug 20;3(8):e293. doi: 10.1038/tp.2013.69.
5
Conformation-dependent oligomers in cerebrospinal fluid of presymptomatic familial Alzheimer's disease mutation carriers.
Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):652-7. doi: 10.1159/000345771. Epub 2012 Dec 15.
6
Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease.
Hum Brain Mapp. 2013 Dec;34(12):3308-19. doi: 10.1002/hbm.22141. Epub 2012 Jul 17.
7
Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease.
Dement Geriatr Cogn Disord. 2012;33(1):1-5. doi: 10.1159/000335729. Epub 2012 Feb 13.
8
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
Br J Clin Pharmacol. 2012 Apr;73(4):504-17. doi: 10.1111/j.1365-2125.2011.04134.x.
9
Defining and describing the pre-dementia stages of familial Alzheimer's disease.
Alzheimers Res Ther. 2011 Sep 27;3(5):29. doi: 10.1186/alzrt91.
本文引用的文献
1
Serial MRI and CSF biomarkers in normal aging, MCI, and AD.
Neurology. 2010 Jul 13;75(2):143-51. doi: 10.1212/WNL.0b013e3181e7ca82.
2
Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
Arch Neurol. 2010 Feb;67(2):217-23. doi: 10.1001/archneurol.2009.316.
3
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064.
4
Biochemical markers in persons with preclinical familial Alzheimer disease.
Neurology. 2008 Jul 8;71(2):85-92. doi: 10.1212/01.wnl.0000303973.71803.81. Epub 2008 May 28.
5
Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.
J Alzheimers Dis. 2007 Nov;12(3):255-60. doi: 10.3233/jad-2007-12307.
6
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
Arch Neurol. 2001 Mar;58(3):373-9. doi: 10.1001/archneur.58.3.373.
7
Clinical comparison of Alzheimer's disease in pedigrees with the codon 717 Val-->Ile mutation in the amyloid precursor protein gene.
Neurobiol Aging. 1993 Sep-Oct;14(5):407-19. doi: 10.1016/0197-4580(93)90099-w.
Zotero 插件